Core Viewpoints - The company announced that its LinX continuous glucose monitoring (CGM) system has recently received market approval in Brazil, further strengthening its international expansion strategy [1] - The CGM product is expected to continue its growth trend in the domestic market through both online and offline channels, while overseas markets show significant potential for revenue growth due to a low revenue base and increasing market share [1][3] - The company reported a net loss of only 2.29 million yuan in the first half of 2025, nearing breakeven, with expectations of achieving profitability by 2026 [1][3] Event Summary - On December 23, 2025, the company announced that its LinX CGM system received market approval in Brazil for both adults and children, enhancing its market presence in Latin America [1] Market Performance - The company reported a 218% increase in GMV during the "Double Eleven" shopping festival, with the second-generation CGM device's shipment volume increasing by 622.8% and new user numbers rising by 300% [2] - The company ranked first in sales on major e-commerce platforms, indicating effective brand promotion [2] R&D Progress - The company is making steady progress in its R&D pipeline, with clinical trials for the AiDEX CGM system for pregnant women completed and the Equil insulin pump system's clinical trial enrollment in Europe finished [2] - The company is exploring AI applications in CGM through internal team formation and collaborations with leading research institutions, aiming to innovate diabetes management [2] Revenue and Profit Outlook - The company expects continued high revenue growth in 2026, with a projected revenue of 5.31 billion yuan in 2025, representing a year-on-year growth of 53.78% [3] - The company anticipates achieving breakeven in 2025 and profitability in 2026, supported by stable gross margins and cost optimization measures [3]
微泰医疗-B(2235.HK)：CGM在巴西市场获批 海外布局持续强化